Departamento de Inmunología, Oftalmología y ORL, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San-Carlos (IdISSC), Madrid, Spain.
Departamento de Inmunología, Oftalmología y ORL, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San-Carlos (IdISSC), Madrid, Spain.
Arch Soc Esp Oftalmol (Engl Ed). 2022 Mar;97(3):161-164. doi: 10.1016/j.oftale.2022.02.002. Epub 2022 Feb 23.
The objective of the present case is to describe a variation in the Preserflo Microshunt surgical technique, placing it in the posterior chamber to minimise the risk of endothelial cell loss in cases with a compromised endothelium. The patient was a 72-year-old pseudophakic woman, with granular dystrophy and a primary diagnosis of open-angle glaucoma presenting with a progressive visual field defect and an IOP of 26 mmHg with maximal medical therapy. The cornea had incipient stromal folds with an endothelial count of 700 cells/mm. A Preserflo Microshunt was implanted in the posterior chamber to minimise the possibility of further damage to the corneal endothelium. Six months after surgery, the implant remains functional. The IOP is 9 mmHg without medications. As far as we know, this is the first Preserflo implanted in the posterior chamber described in the literature.
本病例的目的在于描述一种 Preserflo 微分流管手术技术的变异,将其置于后房以最大程度降低内皮细胞功能不良时内皮细胞丢失的风险。患者为 72 岁女性,无晶状体眼,颗粒状角膜营养不良,原发性开角型青光眼,表现为进行性视野缺损,眼压 26mmHg,经最大药物治疗。角膜出现早期基质皱褶,内皮细胞计数为 700 个/平方毫米。为了最大程度降低对角膜内皮的进一步损伤,在后房植入 Preserflo 微分流管。术后 6 个月,植入物仍然功能正常。眼压 9mmHg,无需药物治疗。据我们所知,这是文献中首次描述的在后房植入的 Preserflo。